Mr. Griffith has extensive leadership experience in the bioprocessing and biopharmaceutical industries, as well as significant commercial and investment banking expertise. Mr. Griffith is the founder of Aptuit, a global contract pharmaceutical research, development and manufacturing company, and served as the company’s chief executive officer from 2004 to 2008.
“Michael’s background in biologics manufacturing is particularly relevant to Repligen, and he also brings valuable financial markets acumen to the board,” said Walter C. Herlihy, president and chief executive officer of Repligen. “In light of the major commitment that we made to bioprocessing with the December acquisition of Novozymes Biopharma (now Repligen Sweden) we welcome Michael’s insight in helping to guide the integration and expansion of this core business. We value the expertise that Michael offers during this exciting time of Repligen’s transition to a fully integrated and commercially focused company.”